LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Innocoll Holdings plc (“Innocoll” or the “Company”) (Nasdaq: INNL). Investors who purchased or otherwise acquired Innocoll shares between November 3, 2016 through December 29, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.
If you are a shareholder who suffered a loss during the Class Period, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
XARACOLL is Innocoll’s lead product candidate. Innocoll filed a New Drug Application (“NDA”) under the U.S. Food & Drug Administration (“FDA”) in October 2016.
On December 29, 2016, Innocoll revealed that it had received a Refusal to File letter from the FDA as to XARACOLL’s NDA. According to Innocoll, the FDA stated that XARACOLL should be considered a drug/device combination and asked Innocoll to submit further information.
When this information was released to the public, the value of Innocoll stock fell up to 66%, causing investors harm.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.